Pharmacological modulation of the natriuretic peptide system

Bibliography

• DE BOLD AJ: Heart atrial granularity: effects of changes in water-electrolyte balance. Proc. Soc. Exp. Biol. Med. (1979) 161:508–511.
   PubMed Web of Science ®Google Scholar
• VENUGOPAL J: Cardiac natriuretic peptides-hope or hype?' Gin. Pharm. Ther. (2001) 26:15–31.
   Google Scholar
• RUSKOAHO H: Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol. Rev (1992) 44:479–602.
   PubMed Web of Science ®Google Scholar
• •Still a useful comprehensive review on natriuretic peptides.
   Google Scholar
• SCHIRGER JA, HEUBLEIN DM, CHEN HH et al.: Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo. Clin. Proc. (1999) 74:126–130.
   PubMed Web of Science ®Google Scholar
• TAKEI Y: Does the natriuretic peptide system exist throughout the animal and plant kingdom? Comp. Biochem. Physiol. B Biochem. Mol. Biol. (2001) 129:559–573.
   PubMed Web of Science ®Google Scholar
• MURTHY KS, TENG BQ, ZHOU H, JIN JG, GRIDER JR, MAKHLOUF GM: G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am. Physiol. Castrointest. Liver Physiol. (2000) 278:G974–G980.
   Web of Science ®Google Scholar
• •Demonstrates that NPR-C has direct cell signalling roles.
   Google Scholar
• GOY ME OLIVER PM, PURDY KE et al.: Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide. Biochem. (2001) 358:379–387.
   Google Scholar
• SUGA S, NAKAO K, HOSODA K et al.: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology (1992) 130:229–239.
   PubMed Web of Science ®Google Scholar
• CHINKERS M, GARBERS DL, CHANG MS et al.: A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature (1989) 338:78–83.
   PubMed Web of Science ®Google Scholar
• POTTER LR, HUNTER T: Phosphorylation of the kinase homology domain is essential for activation of the A-type natriuretic peptide receptor. Mol Cell. Biol. (1998) 18:2164–2172.
   PubMed Web of Science ®Google Scholar
• POTTER LR, HUNTER T: Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor. I. Biol. Chem. (1998) 273:15533–15539.
   Web of Science ®Google Scholar
• BRYAN PM, POTTER LR: The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases. Biol. Chem. (2002) 3:16041–16047.
   Google Scholar
• FOSTER DC, GARBERS DL: Dual rolefor adenine nucleotides in the regulation of the atrial natriuretic peptide receptor, guanylyl cyclase-A. " Biol. Chem. (1998) 273:16311–16318.
   PubMed Web of Science ®Google Scholar
• ITAKURA M, SUZUKI H, HIROSE S: Structural analysis of natriuretic peptide receptor-C by truncation and site-directed mutagenesis. Biochem. (1997) 322\(Pt2):585–590.
   Google Scholar
• CHAUHAN SD, NILSSON H, AHLUWALIA A, HOBBS AJ: Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc. Nati Acad. Sci. USA (2003) 100:1426–1431.
   PubMed Web of Science ®Google Scholar
• ••The first study that explores the mechanismof vasorelaxation induced by NPR-C signalling. It also presents electrophysiological and bioassay data to argue that CNP and EDHF are one and the same.
   Google Scholar
• LEANEY JL, TINKER A: The role of members of the pertussis toxin-sensitive family of G proteins in coupling receptors to the activation of the G-protein-gated inwardly rectifying potassium channel. Proc. Nati Acad. Sri. USA (2000) 97:5651–5656.
   PubMed Web of Science ®Google Scholar
• LEANEY JL, DEKKER LV, TINKER A:Regulation of a G-protein-gated inwardly rectifying K± channel by a Ca2±-independent protein kinase C. Physiol. (2001) 534:367–379.
   Web of Science ®Google Scholar
• VAN DEN AKKER F, ZHANG X, MIYAGI M, HUO X, MISONO KS, YEE VC: Structure of the dimerized hormone-binding domain of a guanylyl-cyclase-coupled receptor. Nature (2000) 406:101–104.
   PubMed Web of Science ®Google Scholar
• MISONO KS: Atrial natriuretic factor binding to its receptor is dependent on chloride concentration: a possible feedback-control mechanism in renal salt regulation. Circ. Res. (2000) 86:1135–1139.
   PubMed Web of Science ®Google Scholar
• KISCH B: Electron microscopy of the atrium of the heart in guinea-pig. Exp. Med. Stow. (1956) 14:99–112.
   Google Scholar
• DE BOLD AJ: Atrial natriuretic factor of the rat heart. Studies on isolation and properties. Proc. Soc. Exp. Biol. Med. (1982) 170:133–138.
   PubMed Web of Science ®Google Scholar
• SUDOH T, KANGAWA K, MINAMINO N, MATSUO H: A new natriuretic peptide in porcine brain. Nature (1988) 332:78–81.
   PubMed Web of Science ®Google Scholar
• SUDOH T, MINAMINO N, KANGAWA K, MATSUO H: C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. (1990) 168:863–870.
   PubMed Web of Science ®Google Scholar
• SCHULZ-KNAPPE P, FORSSMANN K, HERBST F, HOCK D, PIPKORN R, FORSSMANN WG: Isolation and structural analysis of `urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. KIM. Wochenschr. (1988) 66:752–759.
   PubMedGoogle Scholar
• SCHWEITZ H, VIGNE P, MOINIER D, FRELIN C, LAZDUNSKI M: A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). j Biol. Chem. (1992) 267:13928–13932.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-DURANGO R, TRIVINO A, RAMIREZ JM et al: Immunoreactive atrial natriuretic factor in aqueous humor: its concentration is increased with high intraocular pressure in rabbit eyes. Vision Res. (1990) 30:1305–1310.
   PubMed Web of Science ®Google Scholar
• ITOH H, SAGAWA N, HASEGAWA M et al.: Transforming growth factor-I3 stimulates, and glucocorticoids and epidermal growth factor inhibit brain natriuretic peptide secretion from cultured human amnion cells. J. Clin. Endocrinol Metal,. (1994) 79:176–182.
   PubMed Web of Science ®Google Scholar
• CHRISMAN TD, SCHULZ S, POTTER LR, GARBERS DL: Seminal plasma factors that cause large elevations in cellular cyclic GMP are C-type natriuretic peptides. Biol. Chem. (1993) 268:3698–3703.
   Web of Science ®Google Scholar
• HUANG H, ACUFF CG, STEINHELPER ME: Isolation, mapping, and regulated expression of the gene encoding mouse C-type natriuretic peptide. Am. PhysioL (1996) 271:H1565–1575.
   Web of Science ®Google Scholar
• TAKAHASHI T, ALLEN PD, IZUMO S: Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca2+-ATPase gene. Circ. Res. (1992) 71:9–17.
   Google Scholar
• VOLLMAR AM, GERBES AL, NEMER M, SCHULZ R: Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology (1993) 132:1872–1874.
   PubMed Web of Science ®Google Scholar
• KINOSHITA H, FUJIMOTO S, FUKAE H et al.: Plasma and urine levels of uroguanylin, a new natriuretic peptide, in nephrotic syndrome. Nephron (1999) 81:160–164.
   PubMed Web of Science ®Google Scholar
• SAHAI A, GANGULY PK: Atrial natriuretic peptide: pathophysiological considerations. Indian J. Physiol Pharmacol (1992) 36:3–14.
   PubMedGoogle Scholar
• KENNY AJ, BOURNE A, INGRAM J: Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. (1993) 291\(Pt 1):83–88.
   Google Scholar
• QIU WQ, WALSH DM, YE Z et al.: Insulin-degrading enzyme regulates extracellular levels of amyloid-P-protein by degradation.j Biol. Chem. (1998) 273:32730–32738.
   PubMed Web of Science ®Google Scholar
• NUSSENZVEIG DR, LEWICKI JA, MAACK T: Cellular mechanisms of the clearance function of type-C receptors of atrial natriuretic factor. Biol. Chem. (1990) 265:20952–20958.
   Web of Science ®Google Scholar
• HE X, CHOW D, MARTICK MM, GARCIA KC: Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone. Science (2001) 293:1657–1662.
   PubMed Web of Science ®Google Scholar
• ••Crystal structure of the extracellulardomain of NPR-C bound/unbound to CNP is solved in this paper.
   Google Scholar
• UNGER T, BADOER E, GAREIS C et at: Atrial natriuretic peptide (ANP) as a neuropeptide: interaction with angiotensin II on volume control and renal sodium handling. ELI: Clin. Pharmacol (1990) 30(Suppl.):83S–88S.
   Google Scholar
• CARON N, KRAMP R: Measurement of changes in glomerular filtration rate induced by atrial natriuretic peptide in the rat kidney. Exp. Physiol (1999) 84:689–696.
   PubMed Web of Science ®Google Scholar
• CLEMO HF, BAUMGARTEN CM: Atrial natriuretic factor decreases cell volume of rabbit atrial and ventricular myocytes. Am. J. PhysioL (1991) 260:C681–C690.
   Google Scholar
• HIROSE M, FURUKAWA Y, KUROGOUCHI F, NAKAJIMA K, MIYASHITA Y, CHIBA S: C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. j Pharmacol Exp. Ther. (1998) 286:70–76.
   PubMed Web of Science ®Google Scholar
• ROSENKRANZ AC, WOODS RL, DUSTING GJ, RITCHIE RH: Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP Cardiovasc. Res. (2003) 57:515–522.
   Google Scholar
• QIAN JY, HARUNO A, ASADA Y et at: Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ. Res. (2002) 91:1063–1069.
   PubMed Web of Science ®Google Scholar
• •Identifies local cardioprotective effects of CNP that are primarily mediated via the NPR-C receptor.
   Google Scholar
• YAMAHARA K, ITOH H, CHUN TH et al.: Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc. Natl. Acad. Sci. USA (2003) 100:3404–3409.
   PubMed Web of Science ®Google Scholar
• WIECZOREK SJ, WU AH, CHRISTENSON R et al.: A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am. Heart J. (2002) 144:834–839.
   PubMed Web of Science ®Google Scholar
• FAHEY MT, IRWIG L, MACASKILL P: Meta-analysis of Pap test accuracy. Am. EpidemioL (1995) 141:680–689.
   PubMed Web of Science ®Google Scholar
• JACOBSEN SJ, BERGSTRALH EJ, GUESS HA et al: Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch. Intern. Med.(1996) 156:2462–2468.
   PubMedGoogle Scholar
• PAWLOWSKA Z, JERCZYNSKA H, SZEMRAJ J, BARANSKA P, SWIATKOWSKA M, CIERNIEWSKI CS: Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell. MM. Biol. Lett. (2002) 7:1153–1157.
   Google Scholar
• PEDRAM A, RAZANDI M, LEVIN ER: Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology (2001) 142:1578–1586.
   PubMed Web of Science ®Google Scholar
• ITO T, YOSHIMURA M, NAKAMURA S et al.: Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation (2003) 107:807–810.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WT, LOWES BD, FERGUSON DA et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.j Card Fail. (1998) 4:37–44.
   PubMedGoogle Scholar
• ARONSON D, BURGER AJ: Intravenousnesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am. J. Cardiol. (2002) 90:435–438.
   PubMed Web of Science ®Google Scholar
• PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS: Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JA MA (2002) 287:1531–1540.
   PubMed Web of Science ®Google Scholar
• BURGER AJ, HORTON DP, LEJEMTEL T et al.: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. (2002) 144:1102–1108.
   PubMed Web of Science ®Google Scholar
• MUROHARA T, KUGIYAMA K, YASUE H: Interactions of nitrovasodilators, atrial natriuretic peptide and endothelium-derived nitric oxide. I Vasc. Res. (1996) 33:78–85.
   PubMed Web of Science ®Google Scholar
• CEDIDI C, KUSE ER, MEYER M et al: Treatment of acute postoperative renal failure after liver and heart transplantation by urodilatin. Clin. Investig. (1993) 71:435–436.
   PubMedGoogle Scholar
• WIEBE K, MEYER M, WAHLERS T et al.: Acute renal failure following cardiac surgery is reverted by administration of Urodilatin (INN: Ularitide ) Ear: I Med. Res.(1996) 1:259–265.
   Google Scholar
• HUMMEL M, KUHN M, BUB A et al.: Urodilatin, a new therapy to prevent kidney failure after heart transplantation.' Heart Lung Transplant. (1993) 12:209-217; discussion 217–208.
   Google Scholar
• BRENNER P, MEYER M, REICHENSPURNER H et al.: Significance of prophylactic urodilatin (INN: ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation. Ear. Med. Res. (1995) 1:137–143.
   PubMedGoogle Scholar
• MEYER M, PFARR E, SCHIRMER G et al: Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren. Fail. (1999) 21:85–100.
   PubMed Web of Science ®Google Scholar
• ANDREASSI MG, DEL RY S, PALMIERI C, CLERICO A, BIAGINI A, GIANNESSI D: Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Ear. Heart Fail. (2001) 3:407–414.
   PubMed Web of Science ®Google Scholar
• OKOLICANY J, MCENROE GA, GREGORY LC, LEWICKI JA, MAACK T: Effects of small C-ANF receptor ligands on plasma levels of atrial natriuretic factor, blood pressure, and renal function in the rat. Can..]: Physiol. Pharmacol. (1991) 69:1561–1566.
   PubMed Web of Science ®Google Scholar
• BRALET J, SCHWARTZ JC: Vasopeptidase inhibitors: an emerging class of cardiovascular drugs. Trends Pharmacol. Sci. (2001) 22:106–109.
   PubMed Web of Science ®Google Scholar
• ENNEZAT PV, BERLOWITZ M, SONNENBLICK EH, LE JEMTEL TH: Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curt: Cardiol. Rep. (2000) 2:258–262.
   PubMedGoogle Scholar
• JORDE UP, ENNEZAT PV, LISKER J, SURYADEVARA V et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 101:844–846.
   PubMed Web of Science ®Google Scholar
• VAN DEN MEIRACKER AH, MAN IN 'T VELD AJ, ADMIRAAL PJ et al.: Partial escape of angiotensin-converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? " Hypertens. (1992) 10:803–812.
   Google Scholar
• NAKAMURA M, ARAKAWA N, YOSHIDA H, MAKITA S, NIINUMA H, HIRAMORI K: Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am. Heart J. (1998) 135:414–420.
   PubMed Web of Science ®Google Scholar
• FIELITZ J, DENDORFER A, PREGLA R et al.: Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation (2002) 105:286–289.
   PubMed Web of Science ®Google Scholar
• OEFNER C, D'ARCY A, HENNIG M, WINKLER FK, DALE GE: Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon. I Mol. Biol. (2000) 296:341–349.
   Google Scholar
• ••Crystal structure of the extracellulardomain of NEP is solved in this paper.
   Google Scholar
• SKIDGEL RA, ERDOS EG: Cellular carboxypeptidases. brimunol. Rev (1998) 161:129–141.
   PubMed Web of Science ®Google Scholar
• ERDOS EG, SKIDGEL RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. (1989) 3:145–151.
   Google Scholar
• SANI M: Vasopeptidase inhibitor: an emerging class of cardiovascular drugs. Hospital Pharmacy (2001) 8:280–282.
   Google Scholar
• TABRIZCHI R: Omapatrilat. Bristol-Myers Squibb. Curt-. Opin. Investig. Drugs (2001) 2:1414–1422.
   Google Scholar
• TRIPPODO NC, FOX M, MONTICELLO TM, PANCHAL BC, ASAAD MM: Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. Cardiovasc. Pharmacol. (1999) 34:782–790.
   PubMed Web of Science ®Google Scholar
• LAPOINTE N, NGUYEN QT, DESJARDINS JF et al: The effects of pre-pen- and post-myocardial infarction treatment with omapatrilat in rats: effects on survival, arrhythmias, function and remodelling. Am. J. Physiol. Heart Circ. Physiol (2003).
   Google Scholar
• QUASCHNING T, D'USCIO LV, SHAW S, LUSCHER TF: Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension (2001) 37:1108–1113.
   PubMed Web of Science ®Google Scholar
• MILLETTE E, DEMEILLIERS B, WU R et al: Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. Hypertens. (2003) 21:125–135.
   Web of Science ®Google Scholar
• RODRIGUEZ-GOMEZ I, WANGENSTEEN R, ATUCHA NM et al.: Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats. Am. Hypertens. (2003) 16:33–38.
   PubMed Web of Science ®Google Scholar
• BACKLUND T, PALOJOKI E, SARASTE A et al.: Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc. Res. (2003) 57:727–737.
   PubMed Web of Science ®Google Scholar
• DONG Y, ZHOU H, SHAFFER E, ATAMAS N, LIAO WC, WEI C: The cardiovascular actions of omapatrilat in spontaneously hypertensive rats. Curt: Hypertens. Rep. (2001) 3 (Supp1.2):S1–5.
   Google Scholar
• LAPOINTE N, BLAIS C Jr, ADAM A et al: Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. Am. Coll Cardiol. (2002) 39:1692–1698.
   PubMed Web of Science ®Google Scholar
• ARNAL JF, CASTANO C, MAUPAS E et al: Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis (2001) 155:291–295.
   PubMed Web of Science ®Google Scholar
• THOMAS CV, MCDANIEL GM, HOLZGREFE HH et al.: Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. Cardiovasc. Pharmacol. (1998) 32:902–912.
   PubMed Web of Science ®Google Scholar
• MANIU CV, MEYER DM, REDFIELD MM: Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension. Hypertension (2002) 40:528–534.
   PubMed Web of Science ®Google Scholar
• TROUGHTON RW, RADEMAKER MT, POWELL JD et al.: Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension (2000) 36:523–530.
   PubMed Web of Science ®Google Scholar
• WANG CH, LEUNG N, LAPOINTE N et al: Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II Type I receptor blocker. Circulation (2003) 107:1923–1929.
   PubMed Web of Science ®Google Scholar
• MASSIEN C, AZIZI M, GUYENE TT, VESTERQVIST O, MANGOLD B, MENARD J: Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin. Pharmacol Ther. (1999) 65:448–459.
   PubMed Web of Science ®Google Scholar
• AZIZI M, LAMARRE-CLICHE M, LABATIDE-ALAN OREA, BISSERY A, GUYENE TT, MENARD J: Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. J. Am. Soc. Nephrol. (2002) 13:2454–2463.
   PubMed Web of Science ®Google Scholar
• LIAO CLD, CATANZARITI PA, METER A, SWANSON BN, UDERMAN HD: Omapatrilat is not a diuretic: single- and multiple-dose analysis of the urinary excretion of sodium. Am Hypertens. (2000) 13:S–113.
   Google Scholar
• COATS AJ: Omapatrilat-the story of OVERTURE and OCTAVE. Int. Cardiol.(2002) 86:1–4.
   PubMed Web of Science ®Google Scholar
• ROULEAU JL, PFEFFER MA, STEWART DJ et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 356:615–620.
   PubMed Web of Science ®Google Scholar
• •Reports the results of an important clinical trial on omapatrilat.
   Google Scholar
• PACKER M, CALIFF RIVI, KONSTAM MA etal.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation (2002) 106:920–926.
   Google Scholar
• •One of the most important clinical trials of omapatrilat.
   Google Scholar
• KUOPPALA A, SHIOTA N, KOKKONEN JO et al: Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure. I Am. Coll. Cardiol. (2002) 40:119–125.
   PubMed Web of Science ®Google Scholar
• PRADO GN, TAYLOR L, ZHOU X, RICUPERO D, MIERKE DF, POLGAR P: Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. Cell Physiol. (2002) 193:275–286.
   Google Scholar
• WALLIS EJ, RAMSAY LE, HETTIARACHCHI J: Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin. Pharmacol. Ther. (1998) 64:439–449.
   PubMed Web of Science ®Google Scholar
• NORTON GR, WOODIWISS AJ, HARTFORD C et al: Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am.' Hypertens. (1999) 12:563–571.
   PubMed Web of Science ®Google Scholar
• MAKI T, NASA Y, TANONAKA K, TAKAHASHI M, TAKEO S: Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. Pharmacol. Exp. Ther. (2003) 305:97–105.
   PubMed Web of Science ®Google Scholar
• ROBL J, RYONO D: Recent advances in the design and development of vasopeptidase inhibitors. Exp. Opin. Ther. Patents (1999) 9:1665–1677.
   Web of Science ®Google Scholar
• •The only other review that has looked specifically into the issue of patents pertaining to natriuretic peptide system.
   Google Scholar
• LAURENT S, BOUTOUYRIE P, AZIZI Met al: Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension (2000) 35:1148–1153.
   PubMed Web of Science ®Google Scholar
• MARIE C, MOSSIAT C, LECOMTE JM et al.: Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. I Pharmacol. Etip. Ther. (1995) 275:1324–1331.
   PubMed Web of Science ®Google Scholar
• BRALETJ, MARIE C, MOSSIAT C, LECOMTEJM, GROS C, SCHWARTZ JC: Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. I Pharmacol. Exp. Ther. (1994) 270:8–14.
   PubMed Web of Science ®Google Scholar
• MONTEIL T, DANVY D, SIHEL M, LEROUX R, PLAQUEVENT JC: Strategies for access to enantiomerically pure ecadotril, dexecadotril and fasidotril: a review. Mini Rev Med. Chem. (2002) 2:209–217.
   PubMed Web of Science ®Google Scholar
• HUBNER RA, KUB(7fA E, CASLEY DJ, JOHNSTON CI, BURRELL LM: h7 vitro and in vim inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. Hypertens. (2001) 19:941–946.
   Web of Science ®Google Scholar
• TRIPPODO NC, ROBL JA, ASAAD MM, FOX M, PANCHAL BC, SCHAEFFER TR: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Aml. Hypertens. (1998) 11:363–372.
   PubMed Web of Science ®Google Scholar
• •An important study that looks into the effect of omapatrilat on various classes of hypertension.
   Google Scholar
• FRENCH JF, FLYNN GA, GIROUX EL et al.: Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. I Pharmacol. Exp. The]: (1994) 268:180–186.
   PubMed Web of Science ®Google Scholar
• ROUSSO P, BUCLIN T, NUSSBERGERJ, BRUNNER-FERBER F, BRUNNER HR, BIOLLAZ J: Bioavailability of repeated oral administration of MDL-100240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers. Eur. .1 Clin. Pharmacy]. (2000) 55:749–754.
   Google Scholar
• GARDINER SM, KEMP PA, BRUNNER-FERBER F, BENNETT T: Effects of the dual metallopeptidase inhibitor, MDL-100240, on regional haemodynamic responses to vasoactive peptides in conscious rats. Br. Pharmacol (1997) 122:1687–1693.
   PubMed Web of Science ®Google Scholar
• ROUSSO P, BUCLIN T, NUSSBERGERJ, BRUNNER-FERBER F, BRUNNER HR, BIOLLAZ J: Effects of MDL-100240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers. Cardiovasc. Pharmacol. (1998) 31:408–417.
   PubMed Web of Science ®Google Scholar
• GARDINER SM, KEMP PA, BRUNNER-FERBER F, BENNETT T: Comparative effects of the dual metallopeptidase inhibitor, MDL-100240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats. Br. J. Pharmacol. (1997) 122:1694–1701.
   PubMed Web of Science ®Google Scholar
• ROSSI GP, BOVA S, SACCHETTO A: Comparative effects of the dual ACE-NEP inhibitor MDL-100240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension. ilmj Hypertens. (2002) 15:181–188.
   PubMed Web of Science ®Google Scholar
• ROSSI GP, CAVALLIN M, RIZZONI D et al: Dual ACE and NEP inhibitor MDL-100240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin Type 2 receptor. Hypertens. (2002) 20:1451–1459.
   Google Scholar
• WECKLER N: Effects of a chronic treatment with the ACE NEP inhibitor AVE-7688 and ramipril on the endotheliale dysfunktion at the model of the atherogen fed rabbit. PhD thesis (Justus Liebig universio pouring, Germany) (2002)
   Google Scholar
• GONZALEZ VERA W, FOURNIE-ZALUSKI MC, PHAM I, LABOULANDINE I, ROQUES BE MICHEL JB: Hypotensive and natriuretic effects of RB-105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. Pharmacol. Exp. Ther. (1995) 272:343–351.
   PubMed Web of Science ®Google Scholar
• FOURNIE-ZALUSKI MC, GONZALEZ W, TURCAUD S, PHAM I, ROQUES BP, MICHEL JB: Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc. Nati Acad. Sri. USA (1994) 91:4072–4076.
   PubMed Web of Science ®Google Scholar
• BALKAU B, ESCHWEGE E, PAPOZ L et al.: Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. Br. Med. (1993) 307:295–299.
   PubMed Web of Science ®Google Scholar
• ARBIN V, CLAPERON N, FOURNIE-ZALUSKI MC, ROQUES BP, PEYROUX J: Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br. J. Pharmacol. (2001) 133:495–502.
   PubMed Web of Science ®Google Scholar
• SHIUCHI T, CUT TX, WU L et al.: ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension (2002) 40:329–334.
   PubMed Web of Science ®Google Scholar
• KIRPICHNIKOV D, SOWERS JR: Role of ACE inhibitors in treating hypertensive diabetic patients. Carr. Diab. Rep. (2002) 2:251–257.
   PubMedGoogle Scholar
• ARBIN V, CLAPERON N, FOURNIE-ZALUSKI MC, ROQUES BP, PEYROUX J: Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese zucker rats. Cardiovasc. Pharmacol (2003) 41:254–264.
   PubMed Web of Science ®Google Scholar
• LASSILA M, DAVIS BJ, ALLEN TJ, BURRELL LM, COOPER ME, CAO Z: Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Sci. (London) (2003) 104:341–347.
   PubMed Web of Science ®Google Scholar
• FARINA NK, JOHNSTON CI, BURRELL LM: Reversal of cardiac hypertrophy and fibrosis by S-21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. Hypertens. (2000) 18:749–755.
   Google Scholar
• •Demonstration of the anti-hypertrophic effects of VPIs.
   Google Scholar
• MORAZZONI G, ALLIEVI L, BRANCA E: ha vitro and ex vivo characterisation of Z-13752A, a new dual-acting ACE/NEP inhibitor. Ear. Pharmacol. Sci. (1998) 6.
   Google Scholar
• BANI M, COLANTONI A, GUILLAUME M, MACCHI F, MORONI G, PERSIANI S: A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z-13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers. Br. I Gin. Pharmacol. (2000) 50:338–349.
   Web of Science ®Google Scholar
• RASTEGAR MA, MARCHINI F, MORAZZONI G, VEGH A, PAPP JG, PARRATT JR: The effects of Z-13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br. Pharmacol. (2000) 129:671–680.
   PubMed Web of Science ®Google Scholar
• BHAGWATT S, FINK C, GUDE C: a-Mercaptoacyl dipeptides that inhibit angiotensin conveting enzyme and nuetral endopeptidase 24.11. Bioorg. Med. Chem. lett. (1995) 5:735–738.
   Google Scholar
• FINK CA, QIAO Y, BERRY CJ, SAKANE Y, GHAI RD, TRAPANI AJ: New a-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. Med. Chem. (1995) 38:5023–5030.
   Google Scholar
• COHEN D, FINK C, TRAPANI A, WEBB R, ZANE P, CHATELAIN R: CGS-30440: a dual inhibitor of angiotensin converting enzyme and nuetral endopeptidase 24.11. Cardiovasc. Drug Rev (1999) 17:16–38.
   Google Scholar
• ICHINOSE F, ADRIE C, HURFORD WE, BLOCH KD, ZAPOL WM: Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology (1998) 88:410–416.
   PubMed Web of Science ®Google Scholar
• NAGAMINE J, HILL LL, PEARL RG: Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Grit. Care Med. (2000) 28:2420–2424.
   PubMed Web of Science ®Google Scholar
• WEIMANN J, ULLRICH R, HROMI J et al.: Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology (2000) 92:1702–1712.
   PubMed Web of Science ®Google Scholar
• KIM D, RYBALKIN SD, PI X et al.: Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation (2001) 104:2338–2343.
   PubMed Web of Science ®Google Scholar
• MULSCH A, OELZE M, KLOSS S et al.: Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation (2001) 103:2188–2194.
   PubMed Web of Science ®Google Scholar
• SUPAPORN T, SANDBERG SM, BORGESON DD et al.: Blunted eGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Lai (1996) 50: 1718-1725.
   Google Scholar
• VENUGOPAL J, BOYLE N, KELLY J: Identification of the expression of inhibitory subunit of phosphodiesterase-6 in non-retinal murine tissues. Carr. Sci. (2003) 84:1227–1231.
   Google Scholar
• MOVSESIAN MA: Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opin. Investig. Drugs (2000) 9:963–973.
   PubMed Web of Science ®Google Scholar
• BURT VL, CUTLER JA, HIGGINS M et al.: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension (1995) 26:60–69.
   Google Scholar
• CAMPESE VM, LASSETER KC, FERRARIO CM et al.: Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension (2001) 38:1342–1348.
   PubMed Web of Science ®Google Scholar
• •Comparitive study on the anti-hypertensive studies on omapatrilat and lisinopril.
   Google Scholar
• FERDINAND K, SAINI R, LEWIN A, YELLEN L, BARBOSA JA, KUSHNIR E: Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. Am. Hypertens. (2001) 14:788–793.
   PubMed Web of Science ®Google Scholar
• TRIPPODO NC, PANCHAL BC, FOX M: Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. Pharinacol Exp. The]: (1995) 272:619–627.
   PubMed Web of Science ®Google Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• BRUTSAERT DL: Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev (2003) 83:59–115.
   PubMed Web of Science ®Google Scholar
• PERALTA C, BULBENA O, BARGALLO R, PRATS N, GELPI E, ROSELLO-CATAFAU J: Strategies to modulate the deleterious effects of endothelin in hepatic ischemia-reperfusion. Transplantation (2000) 70:1761–1770.
   PubMed Web of Science ®Google Scholar
• MATSUKAWA N, GRZESIK WJ, TAKAHASHI N et al.: The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl. Acad. Sci. USA (1999) 96:7403–7408.
   PubMed Web of Science ®Google Scholar